FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease
Year: 2016
Type: article
Abstract: Tauopathies, including Alzheimer's disease (AD), are associated with the aggregation of modified microtubule associated protein tau. This pathological state of tau is often referred to as "hyperphosphorylated". Due to limitations in technology, an accurate quantitative description of this state is lacking. Here, a mass spectrometry-based assay, FLEXITau, is presented to measure phosphorylation stoichiometry and provide an unbiased quantitative view of the tau post-translational modification (PTM) landscape. The power of this assay is demonstrated by measuring the state of hyperphosphorylation from tau in a cellular model for AD pathology, mapping, and calculating site occupancies for over 20 phosphorylations. We further employ FLEXITau to define the tau PTM landscape present in AD post-mortem brain. As shown in this study, the application of this assay provides mechanistic understanding of tau pathology that could lead to novel therapeutics, and we envision its further use in prognostic and diagnostic approaches for tauopathies.
Source: Analytical Chemistry
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
Funders: U.S. Department of Veterans Affairs, National Multiple Sclerosis Society, National Institutes of Health, U.S. Public Health Service, Tau Consortium, National Institute on Aging, NIH Office of the Director, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke
Awards: G1526255798, TripleTOF 5600 Hybrid Mass Spectrometer, G4146347910, Regulation of SMN and Identification of its Downstream Target, Quantifying post-translational modifications and protein expression by HTP-MS, Frontotemporal Dementia: Genes, Images, and Emotions, New Approaches to Dementia Heterogeneity
OpenAlex ID: W2279268939
